Business
INSERTING and REPLACING GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026
GAITHERSBURG, Md., February 23, 2026--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
About this update from Genedx Holdings Corp.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":232,"url":"https://media.zenfs.com/en/business-wire.com/91e442acb6ecf2b7be96c0ac0ed9680a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m89MTEHdlqYulzLtWc7S6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/91e442acb6ecf2b7be96c0ac0ed9680a","width":480,"height":232}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reported fourth quarter 2025 revenues of $121.0 million with 32% year-over-year growth in exome and genome test revenue (42% excluding a one-time 2024 benefit)","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Accelerated exome and genome volume growth to 34% year-over-year","length":64,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported fourth quarter 2025 adjusted gross margin1 of 71%","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported fourth quarter 2025 adjusted net income1 of $4.4 million","length":65,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reaffirmed full year 2026 guidance of $540 to $555 million in revenue with 33-35% exome and genome growth","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"GeneDx to host conference call today at 8:30 a.m. ET","length":52,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":503,"olType":false},{"type":"text","content":"GAITHERSBURG, Md., February 23, 2026--(BUSINESS WIRE)--Insert the "Software and interpretation services" row in the Volume & Revenue(1) table.","length":156,"tagName":"p"},{"type":"text","content":"The updated release reads:","length":26,"tagName":"p"},{"type":"text","content":"GeneDx Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms Guidance for Full Year 2026","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the fourth quarter and full year of 2025.","length":212,"tagName":"p"},{"type":"text","content":""The unmet need for early, accurate genomic diagnosis is en...